ClinicalTrials.Veeva

Menu

Phenotype Identification Based on Multimodal MRI Analysis of Patients With Bronchial Obstructive Diseases (PIMABOD)

U

University Hospital of Bordeaux

Status

Active, not recruiting

Conditions

Asthma Copd

Treatments

Procedure: MRI

Study type

Interventional

Funder types

Other

Identifiers

NCT04341701
CHUBX 2018/37

Details and patient eligibility

About

The hypothesis is that pulmonary and cardiac proton MRI allows phenotyping of patients with bronchial obstruction by cluster analysis based on quantitative multimodal imaging of bronchi, pulmonary vessels, pulmonary parenchyma, right and left ventricular function, myocardial fibrosis and pulmonary arterial pressure.

Such imaging will also offer the advantage of being non-irradiating and without contrast products, which will ultimately allow CT to be replaced by MRI in the follow-up of bronchial obstructive patients, thus avoiding the risks associated with repeated exposure to ionizing radiation.

Full description

Bronchial obstructive diseases such as asthma and chronic obstructive pulmonary disease (COPD) are very common and represent a major public health problem. The distinction between these two diseases is sometimes difficult. In each of these diseases, several clinical phenotypes or biological endotypes have been defined. For example, frequent exacerbating patients and / or hypereosinophilic patients are present in both diseases. In the severe states, cardiovascular comorbidities are the most frequent comorbidities and alter the prognosis.

In these chronic obstructive patients, computed tomography (CT) allows a multimodal analysis of the bronchial wall, the lung parenchyma and pulmonary vessels. CT also allows a score analysis of coronary plaques. However, irradiation is significant and increases with repeated examinations. CT does not allow a comprehensive analysis of cardiac function, or an estimate of pulmonary artery pressure.

Magnetic Resonance Imaging (MRI) is a proton non-ionizing alternative to CT, in particular when using 3D ultra-short echo-time (UTE) sequences. These 3D-UTE sequences decrease the effects of magnetic susceptibility and provide morphological and morphometric information on bronchi and lung comparable to those obtained by CT. Moreover, dedicated sequences add functional information on bronchi. Heart MRI allows more analyses, such as right and left ventricular systolic functions, an indirect estimate of pulmonary arterial pressure and the amount of diffuse myocardial fibrosis.

Our project aims to identify morphological phenotypes through the pulmonary and heart MRI in patients with obstructive lung disease

.

Enrollment

100 patients

Sex

All

Ages

40 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Man or woman aged between 40 and 70 years.
  • Having benefited under the current care of spirometry showing FEV / FVC pre-bronchodilation <0.70 at steady state (i.e., without exacerbation from at least 4 weeks).
  • Having a diagnosis of asthma according to GINA 2019 without smoking restrictions or COPD according to GOLD 2019 but unrestricted to any level of bronchial reversibility to bronchodilator established by the pulmonologist.
  • On stable cardiopulmonary medications for at least 4 weeks
  • Having given his written informed consent.

Exclusion criteria

  • Subject deprived of liberty by judicial or administrative decision.
  • Major protected by law.
  • Subject not affiliated to a social security scheme, whether or not the beneficiary of such a regime.
  • Pregnant or breastfeeding women
  • Inability to complete the Questionnaire SF-36 and SGQLQ.
  • Subject in times of exclusion in relation to another protocol.
  • History of pulmonary fibrosis, primary pulmonary hypertension and cystic fibrosis.
  • History of lung resection (referred to oncological or volume reduction)
  • History of cancer except skin cancer (squamous and Basal) under 5 years
  • History of chest radiation
  • Pacemaker carrier subject or implantable defibrillator, intraocular metallic foreign body, metal clip intracranial, heart valve prosthesis kind Starr-Edwards pre-6000, or biomedical insulin pump type device, Neurostimulator or cochlear implant, Metal patches.
  • Subject claustrophobic or unable to stay elongate during 30 minutes.
  • Subject with a waist circumference greater than 200 cm.
  • Occurrence of an exacerbation between the FE and MRI
  • Uninterpretable MRI

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

100 participants in 2 patient groups

COPD
Other group
Description:
COPD according to GOLD 2019 but unrestricted to any level of bronchial reversibility established by the pulmonologist
Treatment:
Procedure: MRI
Asthma
Other group
Description:
asthma according to GINA 2019 but without any smoking restriction
Treatment:
Procedure: MRI

Trial contacts and locations

6

Loading...

Central trial contact

Virginie NIEL; Patrick BERGER, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems